<p>在最新的季度中，16 位分析師對 Insmed（NASDAQ: INSM）提供了評級，展現出看漲和看跌的不同觀點。</p>
<p>下表提供了他們最近評級的快速概覽，突顯出過去 30 天情緒的變化，並與前幾個月進行比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師為 Insmed 設定了 12 個月的價格目標，顯示出平均目標為 224.19 美元，最高預估為 269.00 美元，最低預估為 162.00 美元。當前的平均值反映出較之前的平均價格目標 222.00 美元增長了 0.99%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png"/></p>
<h2>深入分析分析師評級：深入探索</h2>
<p>對金融專家如何看待 Insmed 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>等權重</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>宣佈</td>
<td>買入</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>下調</td>
<td>買入</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>下調</td>
<td>買入</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>下調</td>
<td>買入</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>下調</td>
<td>買入</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>上調</td>
<td>超配</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>上調</td>
<td>買入</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上調</td>
<td>超越大盤</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是'維持'、'上調'還是'下調'他們的立場，反映了他們對 Insmed 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 揭示見解，分析師提供了對股票表現的定性見解，從'超越大盤'到'表現不佳'。這些評級傳達了對 Insmed 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 通過獲取見解，分析師提供了對 Insmed 股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>為了獲取有關 Insmed 市場表現的有價值見解，請考慮這些分析師評估以及關鍵財務指標。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 Insmed 分析師評級。</p>
<h2>關於 Insmed</h2>
<p>Insmed Inc 是一家生物製藥公司，致力於改變患有嚴重和罕見疾病患者的生活。該公司的首個商業產品是 ARIKAYCE（阿米卡星脂質體吸入懸液），已在美國獲得批准，用於治療結核分枝桿菌複合體（MAC）肺病，作為成人患者有限或沒有替代治療選擇的抗菌藥物組合的一部分。它還在開發 Brensocatib，一種用於支氣管擴張症和其他中性粒細胞介導疾病的口服可逆性二肽基肽酶 1 抑制劑，以及 Treprostinil Palmitil 吸入粉末，一種用於與間質性肺病和肺動脈高壓相關的肺動脈高壓的吸入型特雷普利酮前藥。</p>
<h3>Insmed 的經濟影響：分析</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模上的限制。這可能受到增長預期或運營能力等因素的影響。</p>
<p><strong>收入增長：</strong> Insmed 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>52.36%</strong>。這表明公司頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Insmed 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司以 <strong>-259.95%</strong> 的淨利潤率有效管理成本，實現強勁盈利能力。</p>
<p><strong>股本回報率（ROE）：</strong> Insmed 的 ROE 落後於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>-33.71%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
<p><strong>資產回報率（ROA）：</strong> Insmed 的 ROA 低於行業平均水平，表明在有效利用資產方面存在挑戰。ROA 為 <strong>-15.29%</strong>，公司可能在從其資產中產生最佳回報方面面臨困難。</p>
<p><strong>債務管理：</strong> Insmed 的債務與股本比率低於行業平均水平。該公司的比率為 <strong>0.61</strong>，這意味着它對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<h2>理解分析師評級的相關性</h2>
<p>在銀行和金融系統領域，分析師專注於特定股票或定義的行業進行報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 &#34;分析師評級&#34;。分析師通常每季度評估和評級每隻股票一次。</p>
<p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。重要的是要認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

<p>在最新的季度中，16 位分析師對 Insmed（NASDAQ:INSM）給出了混合評級，平均 12 個月的目標價格為 224.19 美元，比之前的目標上漲了 0.99%。分析師們經常根據市場情況更新他們的建議，評級和目標價格也會發生顯著變化。Insmed 的收入增長率約為 52.36%，但其淨利潤率和股本回報率低於行業平均水平。該公司的債務與股本比率保持在 0.61，表明對債務融資的依賴較小。分析師評級為股票表現和未來預期提供了洞察</p>

<p>In the latest quarter, 16 analysts provided ratings for Insmed (NASDAQ: INSM), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，16 位分析師對 Insmed（NASDAQ: INSM）提供了評級，展現出看漲和看跌的不同觀點。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快速概覽，突顯出過去 30 天情緒的變化，並與前幾個月進行比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Insmed, revealing an average target of $224.19, a high estimate of $269.00, and a low estimate of $162.00. This current average reflects an increase of 0.99% from the previous average price target of $222.00.</p>
<div class="lb-trans"><p>分析師為 Insmed 設定了 12 個月的價格目標，顯示出平均目標為 224.19 美元，最高預估為 269.00 美元，最低預估為 162.00 美元。當前的平均值反映出較之前的平均價格目標 222.00 美元增長了 0.99%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1771610472_0.png"/></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<div class="lb-trans"><h2>深入分析分析師評級：深入探索</h2>
</div><p>A comprehensive examination of how financial experts perceive Insmed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>對金融專家如何看待 Insmed 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>等權重</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>宣佈</td>
<td>買入</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越大盤</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>下調</td>
<td>買入</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>下調</td>
<td>買入</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>下調</td>
<td>買入</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>下調</td>
<td>買入</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>下調</td>
<td>買入</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超越大盤</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>上調</td>
<td>超配</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>上調</td>
<td>買入</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>上調</td>
<td>買入</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上調</td>
<td>超越大盤</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是'維持'、'上調'還是'下調'他們的立場，反映了他們對 Insmed 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 揭示見解，分析師提供了對股票表現的定性見解，從'超越大盤'到'表現不佳'。這些評級傳達了對 Insmed 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 通過獲取見解，分析師提供了對 Insmed 股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>For valuable insights into Insmed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲取有關 Insmed 市場表現的有價值見解，請考慮這些分析師評估以及關鍵財務指標。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Insmed analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Insmed 分析師評級。</p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>關於 Insmed</h2>
</div><p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<div class="lb-trans"><p>Insmed Inc 是一家生物製藥公司，致力於改變患有嚴重和罕見疾病患者的生活。該公司的首個商業產品是 ARIKAYCE（阿米卡星脂質體吸入懸液），已在美國獲得批准，用於治療結核分枝桿菌複合體（MAC）肺病，作為成人患者有限或沒有替代治療選擇的抗菌藥物組合的一部分。它還在開發 Brensocatib，一種用於支氣管擴張症和其他中性粒細胞介導疾病的口服可逆性二肽基肽酶 1 抑制劑，以及 Treprostinil Palmitil 吸入粉末，一種用於與間質性肺病和肺動脈高壓相關的肺動脈高壓的吸入型特雷普利酮前藥。</p>
</div><h3>Insmed's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Insmed 的經濟影響：分析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模上的限制。這可能受到增長預期或運營能力等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Insmed's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>52.36%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Insmed 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>52.36%</strong>。這表明公司頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Insmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-259.95%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Insmed 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司以 <strong>-259.95%</strong> 的淨利潤率有效管理成本，實現強勁盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Insmed's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-33.71%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Insmed 的 ROE 落後於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>-33.71%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> Insmed's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-15.29%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Insmed 的 ROA 低於行業平均水平，表明在有效利用資產方面存在挑戰。ROA 為 <strong>-15.29%</strong>，公司可能在從其資產中產生最佳回報方面面臨困難。</p>
</div><p><strong>Debt Management:</strong> Insmed's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.61</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Insmed 的債務與股本比率低於行業平均水平。該公司的比率為 <strong>0.61</strong>，這意味着它對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析師評級的相關性</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在銀行和金融系統領域，分析師專注於特定股票或定義的行業進行報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 &#34;分析師評級&#34;。分析師通常每季度評估和評級每隻股票一次。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。重要的是要認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

深入解析 Insmed：16 位分析師分享他們的看法